Publications
321
Citations
34,349
Est. group size
~9
Recurring co-author estimate
Active years
29
Publishing since 1997
This profile centers on clinical and translational cancer research, particularly thyroid cancer and neuroendocrine tumors, including clinical trials testing targeted therapies (kinase inhibitors like lenvatinib and pazopanib) and immunotherapies (pembrolizumab, anti-CTLA-4/anti-PD-1 combinations). The bibliographic record also includes a diverse mix of unrelated clinical topics (wound care, ophthalmology, oral pathology), suggesting the name may be associated with multiple contributors or co-authored studies across different medical fields. Prospective students should note the work draws heavily on multicenter clinical trials and biomarker studies rather than laboratory-based basic science.
Publication output was relatively steady (12-24 per year) from 2017-2022, spiked sharply to 51 in 2023, then declined to around 9-10 in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Comparative Study of Negative Pressure Wound Therapy and Silver-releasing Foam Dressings in the Management of Diabetic Foot Ulcers
Indus journal of bioscience research. · 2025
- Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype
The American Journal of Human Genetics · 2024
- 3′,4′-Dihydroxyflavonol Inhibits Fibrotic Response in a Rabbit Model of Glaucoma Filtration Surgery
International Journal of Molecular Sciences · 2024
- Diagnostic Modalities in Oral Pathology: Integrating Advance Diagnostic Techniques to Differentiate Malignant and Benign Lesions
Pakistan Journal of Health Sciences · 2024
- A Biomarker-Centric Diagnostic Approach based on Neutrophil Percentage to Albumin Ratio (NPAR) for Diabetic UTIs
Pakistan Journal of Health Sciences · 2024
- Platelet-Lymphocyte Ratio (PLR) as an Early Predictor of Severity in Acute Biliary Pancreatitis
Pakistan Armed Forces Medical Journal · 2024
- Financial incentives for influenza vaccination
AEA Randomized Controlled Trials · 2024
- Diabetes Remission After Radical Nephrectomy in a Geriatric Patient With Obesity and Type 2 Diabetes—34 Months’ Follow-Up
JCEM Case Reports · 2024
- Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study
Cancer · 2023
- Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial
The Lancet Oncology · 2023
- From bench to clinic: Emerging therapies for corneal scarring
Pharmacology & Therapeutics · 2023
- Kinase inhibitors in thyroid cancers
Endocrine Oncology · 2023
- Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting
JNCI Journal of the National Cancer Institute · 2023
- A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Endocrine Related Cancer · 2023
- Data from A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
2023
- Journal of Clinical Oncology×20
- Journal of the National Comprehensive Cancer Network×8
- Thyroid×5
- Annals of Oncology×5
- The Journal of Clinical Endocrinology & Metabolism×4
- Ashima Goyal
Medicine · The Ohio State University
- Bhavana Konda
Medicine · The Ohio State University
- Ye Zhou
Medicine · The Ohio State University
- Dramane Konate
Medicine · The Ohio State University
- Vineeth Sukrithan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile